Previous 10 | Next 10 |
2024-01-31 11:34:01 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Presents at J.P. Morgan 42nd Annual Global Healthcare Conference (Transcript) Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating) Teva Pharmaceutical Industries Limi...
2024-01-28 08:00:00 ET As the calendar transitions from January to February, the upcoming week promises a flood of earnings reports from some of the world's largest companies by market capitalization. Among the noteworthy releases are anticipated updates from tech giants Microsoft ( ...
2024-01-27 06:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-26 15:00:55 ET More on SPDR S&P 500 ETF Trust SPY: Black Swan Hiding In Plain Sight 2024 Analyst Outlook: Jussi Askola On Being Selective With REITs, Dividend Investing SPY Is At Its Highest Risk Level (Technical Analysis) Investors withdraw capit...
2024-01-25 14:56:31 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the commitment to bringing t...
2024-01-24 09:00:58 ET Summary Sanofi acquires INBRX-101 from Inhibrx for $2.2 billion, targeting rare disease Alpha-1 Antitrypsin Deficiency (AATD). INBRX-101's monthly dosing offers a potential improvement over weekly treatments in AATD, with a novel AAT-Fc fusion approach. ...
2024-01-23 15:00:40 ET More on GSK GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript) AbbVie Vs. GSK: Dual Dominance In Pharma GSK - Greenshoots In The Horizon GSK sells off partial stake in Haleon for $1.2B GSK to sell 3.2% stake ...
2024-01-23 04:42:01 ET In a bid to strengthen its rare disease portfolio, Sanofi ( NASDAQ: SNY ) has agreed to acquire certain assets from biopharmaceutical company Inhibrx ( NASDAQ: INBX ) in a deal valued at up to $2.2B.... Read the full article on Seeking Alpha ...
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5 , plus 0.25 shares in New Inhibrx, a new publicly traded company ...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...